Page 49 - Vibrational Spectroscopic Imaging for Biomedical Applications

26 Cha pte r O n e

References
1. M. J. Horner, L. A. G. Ries, M. Krapcho, N. Neyman, R. Aminou, N. Howlader,
S. F. Altekruse, et al. (eds.), SEER Cancer Statistics Review, 1975–2006, NCI.
Bethesda, MD, http://seer.cancer.gov/csr/1975–2006/, based on November
2008 SEER data submission, posted to the SEER web site, 2009.
2. R. A. Smith, V. Cokkinides, and O. W. Brawley, “Cancer Screening in the United
States, 2009: A Review of Current American Cancer Society Guidelines and Issues
in Cancer Screening,” CA Cancer Journal for Clinicians, 59:27–41, 2009.
3. Data provided by Thomson Reuters In-Patient and Out-Patient Views, 2008.
4. V. L. Katz, G. Lentz, R. A. Lobo, and D. Gershenson, Comprehensive Gynecology,
5th ed. Mosby, Philadelphia, PA, 2007.
5. D. Carter, Interpretation of Breast Biopsies, 4th ed., Lippincott Williams & Wilkins,
Philadelphia, PA, 2004.
6. J. M. Bueno-de-Mesquita, D. S. Nuyten, J. Wesseling, H. van Tinteren, S. C. Linn,
and M. J. van de Vijver, “The Impact of Inter-Observer Variation in Pathological
Assessment of Node-Negative Breast Cancer on Clinical Risk Assessment
and Patient Selection for Adjuvant Systemic Treatment,” Annals of Oncology,
21(1):40–47, 2010.
7. J. D. Kronz, W. H. Westra, and J. I. Epstein, “Mandatory Second Opinion
Surgical Pathology at a Large Referral Hospital,” Cancer, 86:2426–2438, 1999.
8. M. Simunovic, A. Gagliardi, D. McCready, A. Coates, M. Levine, and D.
DePetrillo, “A Snapshot of Waiting Times for Cancer Surgery Provided by
Surgeons Affiliated with Regional Cancer Centers in Ontario,” Canadian Medical
Association Journal, 165(4):421–425, 2001.
9. S. H. Parker, F. Burbank, R. J. Jackman, C. J. Aucreman, G. Cardenosa, T. M.
Cink, J. L. Coscia, et al., “Percutaneous Large-Core Breast Biopsy: A Multi-
Institutional Study,” Radiology, 193:359–362, 1994.
10. E. V. Lang, K. S. Berbaum, and S. K. Lutgendorf, “Large-Core Breast Biopsy:
Abnormal Salivary Cortisol Profiles Associated with Uncertainty of Diagnosis,”
Radiology, 250(3):631–637, 2009.
11. S. S. Raab, D. M. Grzybicki, J. E. Janosky, R. J. Zarbo, F. A. Meier, C. Jensen, and
S. J. Geyer, “Clinical Impact and Frequency of Anatomic Pathology Errors in
Cancer Diagnosis,” Cancer, 104(10):2205–2213, 2005.
12. E. Rakovitch, A. Mihai, J. Pignol, W. Hanna, J. Kwinter, C. Chartier, I. Ackerman,
J. Kim, K. Pritchard, and L. Paszat, “Is Expert Breast Pathology Assessment
Necessary for the Management of Ductal Carcinoma In Situ?” Breast Cancer
Research and Treatment, 87:265–272, 2004.
13. E. Newman, A. Guest, M. Helvie, M. Roubidoux, A. Chang, C. Kleer, K. Diehl,
et al., “Changes in Surgical Management Resulting From Case Review at a
Multidisciplinary Tumor Board,” Cancer, 107:2346–2351, 2006.
14. S. E. Singletary, and J. L. Connolly, “Breast Cancer Staging: Working with
the Sixth Edition of the AJCC Cancer Staging Manual,” CA Cancer Journal for
Clinicians, 56:37–47, 2006.
15. J. Meyer, C. Alvarez, C. Milikowski, N. Olson, I. Russo, J. Russo, A. Glass,
B. Zehnbauer, K. Lister, and R. Parwaresch, “Breast Carcinoma Malignancy
Grading by Bloom-Richardson System vs. Proliferation Index: Reproducibility
of Grade and Advantages of Proliferation Index,” Modern Pathology, 18:1067–
1078, 2005.
16. N. Bosanquet and K. Sikora, “Scenarios for Change in Cancer Treatment 2004–
2010: Impacts on Insurance,” The Geneva Papers on Risk and Insurance, 29(4):
728–737, 2004.
17. U. Veronesi, P. Boyle, A. Goldhirsch, R. Orecchia, and G. Viale, “Breast Cancer,”
Lancet, 365:1727–1741, 2005.
18. I. Levin and R. Bhargava, “Fourier Transform Infrared Vibrational Spectroscopic
Imaging: Integrating Microscopy and Molecular Recognition,” Annual Review
of Physical Chemistry, 56:429–474, 2005.
19. P. Griffiths, Chemical Infrared Fourier Transform Spectroscopy, John Wiley & Sons,
New York, N.Y., 1975.